Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Oct
25
BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis
Nov
14
New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis
Sep
30
UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis
Jun
12
UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024
Nov
09
Advancing Rheumatic Disease Treatment
Dec
07
The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis
May
23
UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022
May
12
Recognizing the Less Common, but Equally Burdensome, Forms of Arthritis During Arthritis Awareness Month
Jan
21
Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study
